Company intelligence / Profile preview

Antegrin Therapeutics

St. Louis, Missouri, United States

Ownership: Private
Development stage: Other

Overview

Antegrin Therapeutics is a pharmaceutical and biotech company founded in 2012 and based in St. Louis, Missouri, dedicated to discovering and developing novel therapies for fibrotic diseases. The company operates on a small-molecule integrin antagonist platform and has expanded its portfolio to include orally available integrin antagonists. According to available data, the company reported approximately $5.8 million in revenue, though comprehensive information regarding current clinical stage, pipeline programs, key personnel, and acquisition status is not available from the provided search results.

Therapeutic areas: Rare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Antegrin Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antegrin Therapeutics.

Explore the full profile